Evidence map›Paper›PMID 38009165›Full record

Article3 Biotech2023

Triethyl phosphine decorated cerium oxide nanoparticles exhibit selective killing of the unicellular protozoan parasite

Nisha Yadav, Kikku Sharma, Souvik Sengupta, Sanjay Singh

Open access · greenAbstract read
In one paragraph

Article in 3 Biotech, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Nisha YadavDivision of Biological and Life Sciences, School of Arts and Sciences, Central Campus, Ahmedabad University, Navrangpura, Ahmedabad, Gujarat 380009 India.
Kikku SharmaDivision of Biological and Life Sciences, School of Arts and Sciences, Central Campus, Ahmedabad University, Navrangpura, Ahmedabad, Gujarat 380009 India.
Souvik SenguptaDivision of Biological and Life Sciences, School of Arts and Sciences, Central Campus, Ahmedabad University, Navrangpura, Ahmedabad, Gujarat 380009 India.
Sanjay SinghDivision of Biological and Life Sciences, School of Arts and Sciences, Central Campus, Ahmedabad University, Navrangpura, Ahmedabad, Gujarat 380009 India.ORCID 0000-0002-6256-7091
Ahmedabad University · INNational Institute of Animal Biotechnology · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Globally, Leishmaniasis affects underprivileged communities of the nations and chemotherapy remains one of the preferred treatment options. However, the cytotoxicity, side effects, and cost of the present chemotherapies limit their utilization. Auranofin [an organogold compound having significant structural similarity with triethyl-phosphine (TEP)] has been reported as an effective therapy for Leishmaniasis treatment. Considering the high cost of gold and the strong affinity of cerium oxide nanoparticles (CeNPs) to phosphine ligands, we designed TEP-decorated CeNPs (CeNPs-TEP) and used them as a novel antileishmanial agent. The hydrodynamic size of synthesized CeNPs and CeNPs-TEP was observed to be 22.2 ± 3.7 nm and 92.11 ± 6.2 nm, respectively. CeNPs-TEP provided aqueous stability to TEP as TEP alone is extremely unstable in water. Exposure of CeNPs-TEP showed ~ 60 and ~ 82% cell death in Supplementary Information: The online version contains supplementary material available at 10.1007/s13205-023-03813-7.

Indexed as

Antileishmanial nanotherapeuticsCerium oxide nanoparticlesLeishmania donovaniReactive oxygen speciesTriethyl phosphite

Identifiers

PMID38009165
PMCPMC10665285
OpenAlexW4388908735

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.